FDA

The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy Earns FDA Approval for Tricuspid Valve

February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is ...

February 02, 2024

Here is a look at the most-read content during the month of January on dicardiology.com

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Top 10: What Viewers Were Reading in January

It is a new year with lots of new content! Here is a look at the most-read content during the month of January on dicard ...

February 01, 2024

Latest innovation has the potential to reduce anesthesia during minimally invasive procedures

News | Transesophageal Echo (TEE)

New Philips Mini TEE Ultrasound Transducer Helps Improve Cardiac Care for More Patients

January 31, 2024 — Royal Philips, a global leader in health technology, announced that its latest TEE transducer ...

January 31, 2024

News | FDA

W. L. Gore Receives FDA Approval for Lower Profile Gore Viabahn VBX Balloon Expandable Endoprosthesis

January 31, 2024 — As part of efforts to continuously improve medical solutions for patients with complex vascular ...

January 31, 2024

The U.S. Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System.

News | FDA

Boston Scientific Receives FDA Approval for FARAPULSE Pulsed Field Ablation System

January 31, 2024 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) appro ...

January 31, 2024

News | Cardiovascular Education

Cardiac Safety Research Consortium Announces Think Tank Program with FDA Regulators, Industry and Academia Focused on Cardiac Remote Monitoring Trials and AI

January 15, 2024 — A public-private partnership Think Tank, scheduled for Feb. 29-March 1, will be presented by the Card ...

January 15, 2024

FDA cleared, evidence-based AI and machine learning-based algorithm detects heart disease-associated ischemia

News | Artificial Intelligence

Cleerly Launches Cleerly ISCHEMIA Solution for Heart Disease Analysis

January 9, 2024 — Cleerly, the company working to create a new standard of care for the diagnosis of heart disease ...

January 09, 2024

Diagnostic and Interventional Cardiology

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

2023 in Review: A Look at the Year's Top 10 Topics

As the Diagnostic and Interventional Cardiology (DAIC) team welcomes in the New Year, we also have taken a few moments ...

January 05, 2024

Embedded AI and user assistance features of the Siemens Healthineers Somatom, which has received FDA clearance, deliver workflow efficiencies, according to a company statement.

News | Computed Tomography (CT)

Siemens Healthineers Announces FDA Clearance of Somatom Pro.Pulse Dual-Source CT Scanner

December 19, 2023 — Siemens Healthineers announced the Food and Drug Administration (FDA) clearance of the Somatom Pro ...

December 19, 2023

News | Cardiovascular Clinical Studies

Clinical Trial Results from Peerbridge Health Unveil Direct-from-ECG Sleep Apnea Detection Using COR Wearable Platform

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

December 19, 2023

Medtronic plc, a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF).

News | Atrial Fibrillation

Medtronic Creates History with FDA Approval of its Novel PulseSelect Pulsed Field Ablation System to Treat Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

December 14, 2023

The U.S. Food and Drug Administration (FDA) announced Cordis US Corp is recalling its INFINITI Angiographic Catheter due to products being shipped without undergoing sterilization procedures

News | Angiographic Catheter

Cordis US Corp Recalls INFINITI Angiographic Catheter due to Products Being Shipped Without Undergoing Sterilization Procedures

December 7, 2023 — The U.S. Food and Drug Administration (FDA) announced Cordis US Corp is recalling its INFINITI ...

December 07, 2023

Take a look at the news making top headlines during the month of November on dicardiology.com

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

DAIC's Top 10 for November

November was a busy month with many FDA approvals and breaking clinical trial results. Take a look at the news making ...

December 05, 2023

The device would be the first clinical-grade, diagnostic wrist-worn device for long term Afib monitoring

News | Wearables

Clinical Smartwatch Finds Success at Identifying Atrial Fibrillation

December 1, 2023 — As the use of wearable technology grows, smartwatches are marketed across the globe to consumers as a ...

December 01, 2023

First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)

News | FDA

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

November 27, 2023